FMP
Inhibrx Biosciences, Inc.
INBX
NASDAQ
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
13.94 USD
-0.16 (-1.15%)
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
607.64M
892.25M
1.06B
1.31B
1.43B
1.78B
2.22B
2.76B
3.44B
4.29B
29.18M
-54.96M
-9.98M
299.08M
320.56M
153.13M
190.78M
237.68M
296.12M
368.92M
-3.19M
-13.06M
-23.82M
-7.34M
-14.92M
-20.82M
-25.94M
-32.31M
-40.26M
-50.16M
25.98M
-68.02M
-33.8M
291.74M
305.64M
132.31M
164.84M
205.37M
255.86M
318.76M
-
-
-
-
-
-
-
-
-
-
-